Cytokinetics, Incorporated (CYTK)

66,79 +1,22 (+1,86%) In data: 10:20AM EDT. Mercato aperto.

Cytokinetics, Incorporated

350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 624 3000
https://www.cytokinetics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 423

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Robert I. Blum	CEO, President, Principal Financial Officer & Director	1,33M	9,61M	1964
Mr. Robert C. Wong	VP & Chief Accounting Officer	495,72k	N/D	1968
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.	Executive Vice President of Research & Development	839,66k	586,17k	1964
Mr. Andrew M. Callos	Executive VP & Chief Commercial Officer	752,84k	N/D	1969
Dr. James A. Spudich Ph.D.	Co-Founder & Member of Scientific Advisory Board	21,94k	N/D	1942
Mr. Jeff Lotz	Vice President of Sales & Operations	N/D	N/D	N/D
Mr. Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	N/D	N/D	N/D
Mr. Steven M. Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	N/D	N/D	1959
Ms. Kari K. Loeser J.D.	VP & Chief Compliance Officer	N/D	N/D	N/D
Mr. John O. Faurescu Esq.	VP, Associate General Counsel & Corporate Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Cytokinetics, Incorporated al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.